James Witten, MD
Pulmonary Disease · Salem, VANPI 1407827231
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,200 of the $119,311 with a category attached, or 76.4%. GSK accounts for 70.1% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2019 at $26,428 and has fallen 87.1% since, to $3,416 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,155 payments — averaging $103.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$84K
- Sunovion Pharmaceuticals Inc.$10K
- AstraZeneca$4K
- Genentech USA, Inc.$4K
- Boehringer Ingelheim$3K
- Sanofi$2K
- plus $12K from 40 others
What the payments were for
- Consulting fees$1,8402%
- Speaking & faculty fees$91,20076%
- Travel & lodging$3,1803%
- Food & beverage$22,19919%
- Education$8921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$52,331
- LONHALA MAGNAIR$8,819
- ANORO$3,600
- ANORO ELLIPTA$3,600
- XOLAIR$3,296
- FASENRA$885
- PURIFIED CORTROPHIN GEL$793
- BREZTRI$753
- TEZSPIRE$738
- AIRSUPRA$434
- SYMBICORT$315
- BEVESPI AEROSPHERE$315
- IMFINZI$132
- TAGRISSO$132
- DUPIXENT$125
- ACTHAR$118
- CHARTIS CATHETER$107
- ZEPHYR DELIVERY CATHETER$107
- ZEPHYR ENDOBRONCHIAL VALVE$107
- PULMONX CHARTIS TABLET CONSOLE$107
How this compares
$119,311 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,000 | $799,194 |
| OfevNintedanib Esylate | 35 | $456,145 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 14 | $223,003 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 153 | $108,864 |
| NucalaMepolizumab | 29 | $104,866 |
| TezspireTezepelumab-Ekko | 14 | $87,680 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $63,976 |
| Dupixent SyringeDupilumab | 17 | $63,553 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 89 | $62,491 |
| Spiriva RespimatTiotropium Bromide | 55 | $36,253 |
| Arnuity ElliptaFluticasone Furoate | 146 | $35,448 |
| SymbicortBudesonide/Formoterol Fumarate | 102 | $34,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $29,679 |
| Spiriva HandihalerTiotropium Bromide | 41 | $23,191 |
| Fluticasone Propionate HfaFluticasone Propionate | 73 | $22,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $83,616 | $1,037,9221,375 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $3,152 | $554,888179 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $4,388 | $231,367269 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Proair Respiclick | $133 | $14,02252 claims |
| Johnson & JohnsonXarelto | $141 | $6,28711 claims |
| MerckDulera | $115 | $4,24413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Salem
- David KilleenSalem$47K
- Nelson GreeneSalem$31K
- Douglas DorseySalem$18K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.